Methods: Germ-free C3H/HeN mice were sensitized with 60μg Ara h1 (n=20) or h2 (n=18) by three weekly intraperitoneal injections (IP) with alum adjuvant, followed by IP challenge of 500μg of indicated protein. Thirty minutes post-challenge clinical scores were graded (0=no symptoms to 5=death) and body temperatures recorded. ELISA was used to measure presence of protein-specific IgE and mast cell protease in sera.
Results: Germ-free mice sensitized with Ara h1 exhibited significantly less-severe clinical scores (mean=2) compared to mice sensitized with Ara h2 (mean=4) (p<0.05). Hypothermic responses post-challenge [average -2.5(SD=1.6) and -8.8(SD=0.9)°C, respectively (p<0.05)] correlated well with clinical scores.
Conclusions: Preliminary results based on clinical scores and hypothermia confirm that the germ-free C3H/HeN mouse model can differentiate between the potency of Ara h1 and h2 as reported in previous in vitro and in vivo analyses of human subjects. While further analysis of additional known allergens is needed, this model shows promise as a risk assessment tool for prediction of allergenicity of novel food proteins.